{"id":744990,"date":"2014-05-06T07:40:00","date_gmt":"2014-05-06T07:40:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-fda-acceptance-for-review-of-mk-3475-biologics-license-application-for-advanced-melanoma\/"},"modified":"2023-03-22T00:04:55","modified_gmt":"2023-03-22T04:04:55","slug":"merck-announces-fda-acceptance-for-review-of-mk-3475-biologics-license-application-for-advanced-melanoma","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-fda-acceptance-for-review-of-mk-3475-biologics-license-application-for-advanced-melanoma\/","title":{"rendered":"Merck Announces FDA Acceptance for Review of MK-3475 Biologics License Application for Advanced Melanoma"},"content":{"rendered":"<p class=\"bwalignc\">       Priority Review Designation for MK-3475 BLA for Proposed Indication        of Unresectable or Metastatic Melanoma in Patients Who Have Been        Previously Treated with Ipilimumab     <\/p>\n<p class=\"bwalignc\">       Advancing New Phase 3 Studies with MK-3475 in Adjuvant Melanoma,        Previously-Untreated Non-Small Cell Lung Cancer, Advanced Head &amp; Neck        and Bladder Cancers     <\/p>\n<p class=\"bwalignc\">       Data from Studies in Three Different Cancer Types to be presented at        2014 ASCO Annual Meeting     <\/p>\n<p class=\"bwalignc\">       Initiating Phase 1 Study with Investigational Anti-GITR Antibody        (MK-4166)     <\/p>\n<p>BOSTON&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\" rel=\"noopener\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced that the U.S. Food and Drug Administration (FDA) has<br \/>\n      accepted for review the Biologics License Application (BLA) for MK-3475,<br \/>\n      Merck\u2019s investigational anti-PD-1 antibody, for the treatment of<br \/>\n      unresectable or metastatic melanoma in patients who have been previously<br \/>\n      treated with ipilimumab. The FDA granted Priority Review designation<br \/>\n      with a PDUFA date of October 28, 2014, and the MK-3475 BLA will be<br \/>\n      reviewed under the FDA\u2019s Accelerated Approval program. The FDA<br \/>\n      previously granted MK-3475 Breakthrough Therapy designation for advanced<br \/>\n      melanoma, the most dangerous type of skin cancer. If approved by the<br \/>\n      FDA, MK-3475 has the potential to be the first anti-PD-1 antibody in a<br \/>\n      new class of immune checkpoint modulators.\n    <\/p>\n<p>\n      Merck also announced it plans to file a Marketing Authorization<br \/>\n      Application for MK-3475 in Europe for advanced melanoma by the end of<br \/>\n      2014.\n    <\/p>\n<p>\n      \u201cPatients with advanced melanoma have few therapeutic options and often<br \/>\n      fail to respond to all available treatments,\u201d said Dr. Roger M.<br \/>\n      Perlmutter, president, Merck Research Laboratories. \u201cWe are hopeful that<br \/>\n      the FDA, through their priority review of our application, will agree to<br \/>\n      make MK-3475 available to patients with advanced melanoma who have no<br \/>\n      other therapeutic options.\u201d\n    <\/p>\n<p>\n      <b>MK-3475 Development Ongoing in 30 Tumors, as Monotherapy and in<br \/>\n      Combination<\/b>\n    <\/p>\n<p>\n      Today, Merck highlighted progress on the advancement of the MK-3475<br \/>\n      development program \u2013 currently ongoing in 30 tumor types as monotherapy<br \/>\n      and in combination. It is anticipated that by the end of 2014, the<br \/>\n      MK-3475 development program will grow to more than 24 clinical trials<br \/>\n      across 30 different tumor types, enrolling an estimated 6,000 patients<br \/>\n      at nearly 300 clinical trial sites worldwide, including four new Phase 3<br \/>\n      studies. Ongoing and planned late-stage monotherapy and combination<br \/>\n      studies include:\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        <b>Seven Phase 3 registrational trials<\/b> spanning advanced melanoma<br \/>\n        (adjuvant, ipilimumab-na\u00efve, and ipilimumab-refractory), advanced<br \/>\n        non-small cell lung cancer (NSCLC) (previously-treated and<br \/>\n        previously-untreated), advanced head &amp; neck cancer and advanced<br \/>\n        bladder cancer; and,\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <b>Ten combination studies<\/b>, including advanced melanoma, advanced<br \/>\n        NSCLC, advanced renal cell carcinoma, HER2+ breast cancer and other<br \/>\n        solid tumors.\n      <\/li>\n<\/ul>\n<p>\n      Merck also said today that based on encouraging preclinical data, it<br \/>\n      plans to initiate a Phase 1 dose-ranging study with its investigational<br \/>\n      anti-GITR agonistic antibody, MK-4166, in patients with advanced<br \/>\n      malignances. GITR (glucocorticoid-induced TNFR receptor) is an<br \/>\n      activating immune checkpoint receptor, which is believed to stimulate<br \/>\n      immune activity against cancer cells. This will be the second<br \/>\n      investigational immune checkpoint antibody within Merck\u2019s<br \/>\n      immuno-oncology discovery program to enter clinical development.\n    <\/p>\n<p>\n      Dr. Perlmutter added, \u201cOur priority is advancing breakthrough<br \/>\n      immunomodulatory molecules that reveal the ability of the immune system<br \/>\n      to eliminate cancer cells. While MK-3475 provides a firm foundation for<br \/>\n      Merck\u2019s research and development strategy in oncology, we are also<br \/>\n      advancing a broad pipeline of immune checkpoint agonists and<br \/>\n      antagonists.\u201d\n    <\/p>\n<p>\n      <b>MK-3475 Presentations at 2014 ASCO Annual Meeting<\/b>\n    <\/p>\n<p>\n      At the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting,<br \/>\n      Merck will have more than 15 company-sponsored abstracts on MK-3475,<br \/>\n      including six oral presentations. Clinical data will be presented from<br \/>\n      studies in advanced melanoma, advanced NSCLC, as well as advanced head &amp;<br \/>\n      neck cancer, which is the first time data for MK-3475 will be presented<br \/>\n      in this cancer type.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=50858610&amp;newsitemid=20140506005958&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=1&amp;md5=e6eccab07e7dd51cd83f01d1eb0a89d2\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Fmerck&amp;esheet=50858610&amp;newsitemid=20140506005958&amp;lan=en-US&amp;anchor=Twitter&amp;index=2&amp;md5=4cdd20e25368404be1f281e37a13bd1d\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2Fmerckbewell&amp;esheet=50858610&amp;newsitemid=20140506005958&amp;lan=en-US&amp;anchor=Facebook&amp;index=3&amp;md5=6ca5b21ee84a742c585f045fce0ab094\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2Fmerck&amp;esheet=50858610&amp;newsitemid=20140506005958&amp;lan=en-US&amp;anchor=YouTube&amp;index=4&amp;md5=b94a184c3c00aa6d9fcd52adca71111d\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Merck Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include, but are not limited to, general<br \/>\n      industry conditions and competition; general economic factors, including<br \/>\n      interest rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and healthcare legislation in the<br \/>\n      United States and internationally; global trends toward healthcare cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2013 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=50858610&amp;newsitemid=20140506005958&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=5&amp;md5=d99ec59fbe58802dd6fda4b161980efa\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20140506005958r1&amp;sid=hq1sf1&amp;distro=nx\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Ian McConnell, 973-901-5722<br \/>Claire Mulhearn,        908-423-7425<br \/>or<br \/>Investors:<br \/>Carol Ferguson, 908-423-4465<br \/>Justin        Holko, 908-423-5088     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for MK-3475, Merck\u2019s investigational anti-PD-1 antibody, for the treatment of unresectable or metastatic melanoma in patients who have been previously treated with ipilimumab. The FDA granted Priority Review designation with a PDUFA date of October 28, 2014, and the MK-3475 BLA will be reviewed under the FDA\u2019s Accelerated Approval program. The FDA previously granted MK-3475 Breakthrough Therapy designation for advanced melanoma, the most dangerous type of skin cancer. If approved by the FDA, MK-3475 has the potential to be the first anti-PD-1 antibody in a new class of immune checkpoint modulators. Merck also announced it plans to file a Marketing Authorization Application for MK-3475 in Europe for advanced melanoma by the end of 2014. \u201cPatients with advanced melanoma have few therapeutic<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,137,138,289,56],"class_list":["post-744990","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology","tag-oncology-newsroom","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Announces FDA Acceptance for Review of MK-3475 Biologics License Application for Advanced Melanoma - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-fda-acceptance-for-review-of-mk-3475-biologics-license-application-for-advanced-melanoma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Announces FDA Acceptance for Review of MK-3475 Biologics License Application for Advanced Melanoma - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for MK-3475, Merck\u2019s investigational anti-PD-1 antibody, for the treatment of unresectable or metastatic melanoma in patients who have been previously treated with ipilimumab. The FDA granted Priority Review designation with a PDUFA date of October 28, 2014, and the MK-3475 BLA will be reviewed under the FDA\u2019s Accelerated Approval program. The FDA previously granted MK-3475 Breakthrough Therapy designation for advanced melanoma, the most dangerous type of skin cancer. If approved by the FDA, MK-3475 has the potential to be the first anti-PD-1 antibody in a new class of immune checkpoint modulators. Merck also announced it plans to file a Marketing Authorization Application for MK-3475 in Europe for advanced melanoma by the end of 2014. \u201cPatients with advanced melanoma have few therapeutic\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-fda-acceptance-for-review-of-mk-3475-biologics-license-application-for-advanced-melanoma\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-fda-acceptance-for-review-of-mk-3475-biologics-license-application-for-advanced-melanoma\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-fda-acceptance-for-review-of-mk-3475-biologics-license-application-for-advanced-melanoma\\\/\",\"name\":\"Merck Announces FDA Acceptance for Review of MK-3475 Biologics License Application for Advanced Melanoma - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2014-05-06T07:40:00+00:00\",\"dateModified\":\"2023-03-22T04:04:55+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-fda-acceptance-for-review-of-mk-3475-biologics-license-application-for-advanced-melanoma\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-fda-acceptance-for-review-of-mk-3475-biologics-license-application-for-advanced-melanoma\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-fda-acceptance-for-review-of-mk-3475-biologics-license-application-for-advanced-melanoma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Announces FDA Acceptance for Review of MK-3475 Biologics License Application for Advanced Melanoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Announces FDA Acceptance for Review of MK-3475 Biologics License Application for Advanced Melanoma - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-fda-acceptance-for-review-of-mk-3475-biologics-license-application-for-advanced-melanoma\/","og_locale":"en_US","og_type":"article","og_title":"Merck Announces FDA Acceptance for Review of MK-3475 Biologics License Application for Advanced Melanoma - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for MK-3475, Merck\u2019s investigational anti-PD-1 antibody, for the treatment of unresectable or metastatic melanoma in patients who have been previously treated with ipilimumab. The FDA granted Priority Review designation with a PDUFA date of October 28, 2014, and the MK-3475 BLA will be reviewed under the FDA\u2019s Accelerated Approval program. The FDA previously granted MK-3475 Breakthrough Therapy designation for advanced melanoma, the most dangerous type of skin cancer. If approved by the FDA, MK-3475 has the potential to be the first anti-PD-1 antibody in a new class of immune checkpoint modulators. Merck also announced it plans to file a Marketing Authorization Application for MK-3475 in Europe for advanced melanoma by the end of 2014. \u201cPatients with advanced melanoma have few therapeutic","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-fda-acceptance-for-review-of-mk-3475-biologics-license-application-for-advanced-melanoma\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:55+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-fda-acceptance-for-review-of-mk-3475-biologics-license-application-for-advanced-melanoma\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-fda-acceptance-for-review-of-mk-3475-biologics-license-application-for-advanced-melanoma\/","name":"Merck Announces FDA Acceptance for Review of MK-3475 Biologics License Application for Advanced Melanoma - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2014-05-06T07:40:00+00:00","dateModified":"2023-03-22T04:04:55+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-fda-acceptance-for-review-of-mk-3475-biologics-license-application-for-advanced-melanoma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-fda-acceptance-for-review-of-mk-3475-biologics-license-application-for-advanced-melanoma\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-fda-acceptance-for-review-of-mk-3475-biologics-license-application-for-advanced-melanoma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Announces FDA Acceptance for Review of MK-3475 Biologics License Application for Advanced Melanoma"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"5087647d-8cd7-4279-a716-3193638730ff","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-Announces-FDA-Acceptance-for-Review-of-MK-3475-Biologics-License-Application-for-Advanced-Melanoma-2014.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/744990","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/744990\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=744990"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=744990"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}